Matthew Weston
Stock Analyst at UBS
(4.39)
# 1,243
Out of 5,060 analysts
348
Total ratings
70.8%
Success rate
10.1%
Average return
Main Sectors:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: NOVN Novartis AG | Reiterated: Hold | CHF 116.00 | CHF 124.70 | -6.98% | 50 | Oct 15, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | CHF 376.00 | CHF 379.20 | -0.84% | 56 | Oct 15, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €62.00 | €44.46 | +39.45% | 25 | Oct 15, 2026 | |
| ETR: MRK Merck KGaA | Reiterated: Hold | €150.00 | €144.30 | +3.95% | 39 | Oct 15, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €300.00 | €261.00 | +14.94% | 31 | Oct 15, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Reiterated: Buy | €260.00 | €215.00 | +20.93% | 18 | Oct 15, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €78.00 | €71.94 | +8.42% | 18 | Oct 15, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 1,940p | 1,863p | +4.16% | 20 | Oct 15, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Buy | CHF 200.00 | CHF 176.05 | +13.60% | 13 | Sep 10, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 17,600p | 12,446p | +41.41% | 68 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $145.95 | n/a | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 750.00 | CHF 604.00 | n/a | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €95.00 → €72.00 | €149.00 | n/a | 3 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $310 | $38.83 | n/a | 3 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $150.62 | n/a | 1 | Jul 5, 2017 |
Novartis AG
Oct 15, 2026
Reiterated: Hold
Price Target: CHF 116.00
Current: CHF 124.70
Upside: -6.98%
Roche Holding AG
Oct 15, 2026
Reiterated: Buy
Price Target: CHF 376.00
Current: CHF 379.20
Upside: -0.84%
Bayer Aktiengesellschaft
Oct 15, 2026
Reiterated: Buy
Price Target: €62.00
Current: €44.46
Upside: +39.45%
Merck KGaA
Oct 15, 2026
Reiterated: Hold
Price Target: €150.00
Current: €144.30
Upside: +3.95%
Sartorius Aktiengesellschaft
Oct 15, 2026
Reiterated: Buy
Price Target: €300.00
Current: €261.00
Upside: +14.94%
Sartorius Stedim Biotech S.A.
Oct 15, 2026
Reiterated: Buy
Price Target: €260.00
Current: €215.00
Upside: +20.93%
Sanofi
Oct 15, 2026
Reiterated: Hold
Price Target: €78.00
Current: €71.94
Upside: +8.42%
GSK plc
Oct 15, 2026
Reiterated: Hold
Price Target: 1,940p
Current: 1,863p
Upside: +4.16%
Galderma Group AG
Sep 10, 2026
Reiterated: Buy
Price Target: CHF 200.00
Current: CHF 176.05
Upside: +13.60%
AstraZeneca PLC
Aug 4, 2026
Reiterated: Buy
Price Target: 17,600p
Current: 12,446p
Upside: +41.41%
Nov 1, 2024
Reiterated: Buy
Price Target: $125
Current: $145.95
Upside: n/a
Jan 27, 2022
Reiterated: Buy
Price Target: CHF 750.00
Current: CHF 604.00
Upside: n/a
Feb 11, 2020
Upgraded: Hold
Price Target: €95.00 → €72.00
Current: €149.00
Upside: n/a
Nov 2, 2018
Reiterated: Hold
Price Target: $310
Current: $38.83
Upside: n/a
Jul 5, 2017
Downgraded: Sell
Price Target: n/a
Current: $150.62
Upside: n/a